BRINGING CLINICIANS TOGETHER TO DISCUSS CURRENT DRUG THERAPY

March 2019 • Vol. 16, No. 3
The following succinct analysis appeared in Pharmacist’s Letter. Based on vol. 35. No. 3

STROKE

More patients will be discharged on a SHORT course of aspirin plus clopidogrel after a minor ischemic stroke or high-risk TIA.

We know aspirin ALONE is generally used to prevent another stroke.

But you’ll see growing acceptance of DUAL antiplatelet therapy in these patients. It’s already an option in guidelines...based on positive outcomes in Chinese patients using it for 3 weeks.

Now there’s evidence the combo benefits a broader population. This is a big deal...since recurrent strokes can be disabling.

Using low-dose aspirin plus clopidogrel prevents another stroke within the next 3 months in about one in 50 patients versus aspirin alone.

The combo may cause major bleeding in up to one in 200 patients...but doesn’t seem to increase intracranial bleeding.

Expect to see more of your patients getting aspirin 81 mg/day plus clopidogrel 75 mg/day after a minor ischemic stroke or high-risk TIA.

Don’t suggest starting the second antiplatelet AFTER discharge. Explain that “earlier is better”...and there’s not much evidence of benefit if the combo’s started more than 24 hours poststroke.

Confirm that one antiplatelet, usually clopidogrel, is stopped within 21 days...or possibly as soon as 10 days for patients at higher bleeding risk. This seems to be the “sweet spot” to maximize benefit and limit bleeding. Then advise continuing aspirin 81 mg/day ALONE long-term.

But clarify WHY the patient’s taking aspirin plus clopidogrel. For example, a recent coronary stent may need the combo for a longer duration.

See our chart, Antiplatelets for Recurrent Ischemic Stroke, for pros and cons of the various regimens and the role of other meds.

(For more on this topic, see Clinical Resource #350303 at PharmacistsLetter.com.)


See LEADER NOTES for answers to discussion questions.
DISCUSSION QUESTIONS

OVERVIEW OF CURRENT THERAPY

1. What is known about antiplatelet regimens for prevention of recurrent ischemic stroke?

ANALYSIS OF NEW STUDY

2. What type of study was this?

3. What was the search strategy for identification of information?

4. How were studies selected for inclusion in the meta-analysis?

5. How were data extracted and analyzed from selected studies?

6. How many studies were identified? What was the patient population?

See LEADER NOTES for answers to discussion questions.
7. What were the results of the meta-analysis?

8. What were the strengths and limitations of the meta-analysis?

9. Were the results expressed in terms we care about and can use?

HOW SHOULD THE NEW FINDINGS CHANGE CURRENT THERAPY?

10. Do the results change your practice? How?

APPLY THE NEW FINDINGS TO THE FOLLOWING CASE

MK is an 82-year-old female with a past medical history of hypertension, COPD, and long-standing type 2 diabetes. She is seeing you in clinic for hospital follow-up after a high-risk TIA (ABCD² score of five).

On discharge, MK was started on aspirin 81 mg daily plus clopidogrel 75 mg daily. In addition, MK is taking amlodipine 10 mg daily, lisinopril 40 mg daily, metformin 1,000 mg twice daily, insulin glargine 28 units at bedtime, pravastatin 10 mg daily, tiotropium inhaler two puffs daily, and albuterol inhaler every six hours as needed. MK smokes, but is down to five cigarettes per day.
MK is accompanied by her son, who is moving in to help take care of her. MK lived with her husband until eight months ago when he passed away after a complicated hospital stay due to a GI bleed.

MK’s vitals today are BP 149/84 mmHg, HR 73, O2 Sats 96% on room air, BMI 28.

11. What are the benefits and risks of DAPT after a minor ischemic stroke or high-risk TIA?

As expected, MK and her son are very concerned about the risk of bleeding with DAPT due to her husband’s recent death due to GI bleeding.

12. What should you consider to limit MK’s risk of bleeding due to DAPT?

You discuss the risks and benefits of DAPT, and emphasize that MK should only use it short-term, followed by a switch to low-dose aspirin alone. MK and her son agree that the benefits of DAPT seem to outweigh the risk, and they agree with continuing the short course.

In addition, they ask about other ways to limit MK’s risk of another TIA or stroke.

13. What additional measures should you recommend to decrease MK’s risk of recurrent TIA or stroke?

MK and her son are willing to add chlorthalidone 25 mg daily to her regimen and track her blood pressure at home. She is also in agreement to switch to atorvastatin 20 mg. MK’s last A1C was 7.8% and she will continue to work on keeping her sugars under control.

See LEADER NOTES for answers to discussion questions.
REFERENCES


Additional Pharmacist’s Letter Resources available at PharmacistsLetter.com

Pharmacist’s Letter Journal Club Editors:

Lori Dickerson, PharmD, FCCP, Editor; Jennifer Nieman, PharmD, BCPS, Associate Editor; Lisa D. Mims, MD, Department of Family Medicine, Medical Univ of South Carolina, Charleston, SC; Maribeth Porter, MD, Department of Community Health and Family Medicine, Univ of Florida, Gainesville, FL, Contributing Editors.

DISCLOSURE:
The editors of this activity and its publisher, Therapeutic Research Center (TRC), have no relevant financial interests related to the products or services covered by this activity. TRC does not receive any commercial support and does not accept any advertising. It is completely independent and is supported entirely by subscriptions. TRC focuses on delivering completely objective, unbiased drug information and advice for the benefit of subscribers.

See LEADER NOTES for answers to discussion questions.